BEAM Stock - Beam Therapeutics Inc.
Unlock GoAI Insights for BEAM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $63.52M | $377.71M | $60.92M | $51.84M | $24,000 |
| Gross Profit | $-304,043,000 | $377.71M | $-250,674,000 | $-180,290,000 | $-103,155,000 |
| Gross Margin | -478.7% | 100.0% | -411.5% | -347.8% | -429812.5% |
| Operating Income | $-415,568,000 | $-176,485,000 | $-338,479,000 | $-392,465,000 | $-132,759,999 |
| Net Income | $-376,742,000 | $-132,527,000 | $-289,088,000 | $-370,638,000 | $-194,592,000 |
| Net Margin | -593.1% | -35.1% | -474.5% | -714.9% | -810800.0% |
| EPS | $-4.58 | $-1.72 | $-4.13 | $-5.77 | $-5.49 |
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Visit WebsiteEarnings History & Surprises
BEAMEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $-1.13 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.98 | $-1.10 | -12.2% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-1.04 | $-1.00 | +3.8% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-1.11 | $-1.24 | -11.7% | ✗ MISS |
Q1 2025 | Feb 25, 2025 | $-1.25 | $-1.09 | +12.8% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $-1.13 | $-1.17 | -3.5% | ✗ MISS |
Q3 2024 | Aug 6, 2024 | $-1.13 | $-1.11 | +1.8% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-1.45 | $-1.21 | +16.6% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-1.01 | $1.73 | +271.3% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-1.37 | $-1.22 | +10.9% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-1.38 | $-1.08 | +21.7% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $-1.36 | $-1.33 | +2.2% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-1.32 | $-0.54 | +59.1% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-1.30 | $-1.56 | -20.0% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-1.08 | $-1.02 | +5.6% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-1.10 | $-1.01 | +8.2% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-1.02 | $-0.85 | +16.7% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-0.78 | $-0.42 | +46.2% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-0.58 | $-0.95 | -63.8% | ✗ MISS |
Latest News
Frequently Asked Questions about BEAM
What is BEAM's current stock price?
What is the analyst price target for BEAM?
What sector is Beam Therapeutics Inc. in?
What is BEAM's market cap?
Does BEAM pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BEAM for comparison